[go: up one dir, main page]

LT99131A - Compounds and compositions for treating diseases associated with serine protease, particularly tryptase, acitivity - Google Patents

Compounds and compositions for treating diseases associated with serine protease, particularly tryptase, acitivity

Info

Publication number
LT99131A
LT99131A LT99-131A LT99131A LT99131A LT 99131 A LT99131 A LT 99131A LT 99131 A LT99131 A LT 99131A LT 99131 A LT99131 A LT 99131A
Authority
LT
Lithuania
Prior art keywords
acitivity
compositions
compounds
serine protease
diseases associated
Prior art date
Application number
LT99-131A
Other languages
Lithuanian (lt)
Other versions
LT4704B (en
Inventor
Timothy J. Church
Neil Scott Cutshall
Anthony R. Gangloff
Thomas E. Jenkins
Martin S. Linsell
Joane Litvak
Kenneth D. Rice
Jeffrey R. Spencer
Vivian R. Wang
Original Assignee
Axys Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axys Pharmaceuticals, Inc. filed Critical Axys Pharmaceuticals, Inc.
Publication of LT99131A publication Critical patent/LT99131A/en
Publication of LT4704B publication Critical patent/LT4704B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LT99-131A 1997-04-07 1999-11-05 Compounds and compositions for treating diseases associated with serine protease, particularly tryptase, acitivity LT4704B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83367497A 1997-04-07 1997-04-07

Publications (2)

Publication Number Publication Date
LT99131A true LT99131A (en) 2000-04-25
LT4704B LT4704B (en) 2000-09-25

Family

ID=25264996

Family Applications (1)

Application Number Title Priority Date Filing Date
LT99-131A LT4704B (en) 1997-04-07 1999-11-05 Compounds and compositions for treating diseases associated with serine protease, particularly tryptase, acitivity

Country Status (16)

Country Link
EP (1) EP1019382A1 (en)
JP (1) JP2001519806A (en)
KR (1) KR20010006119A (en)
CN (1) CN1251579A (en)
AU (1) AU752064B2 (en)
CA (1) CA2285454A1 (en)
EE (1) EE04055B1 (en)
HU (1) HUP0001522A3 (en)
LT (1) LT4704B (en)
LV (1) LV12495B (en)
NO (1) NO314183B1 (en)
NZ (1) NZ500029A (en)
PL (1) PL336233A1 (en)
SI (1) SI20115A (en)
SK (1) SK136799A3 (en)
WO (1) WO1998045275A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221914B1 (en) 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
AU1608399A (en) * 1997-11-26 1999-06-15 Axys Pharmaceuticals, Inc. Substituted amidinoaryl derivatives and their use as anticoagulants
WO1999026932A1 (en) * 1997-11-26 1999-06-03 Axys Pharmaceuticals, Inc. By amidino group substituted heterocyclic derivatives and their use as anticoagulants
GT199900167A (en) * 1998-10-01 2001-03-21 NEW BIS-BENZIMIDAZOLES.
AU1099000A (en) * 1998-10-05 2000-04-26 Axys Pharmaceuticals, Inc. Novel compounds and compositions for treating hepatitis c infections
EP1189889B1 (en) * 1999-06-04 2003-12-17 Elan Pharma International Limited Compositions and methods for inhibiting cell death
DE19953899A1 (en) * 1999-11-10 2001-05-17 Boehringer Ingelheim Pharma Carboxamide-substituted benzimidazole derivatives, process for their preparation and their use as medicaments
WO2001052883A1 (en) * 2000-01-20 2001-07-26 Amgen Inc. Inhibitors of protease-activated receptor-2 (par-2) as novel asthma therapeutics
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
DE10048715A1 (en) * 2000-09-30 2004-05-19 Grünenthal GmbH Use of amino acid for the treatment of pain
WO2002070491A1 (en) * 2001-03-01 2002-09-12 Shionogi & Co., Ltd. Nitrogenous heteroaromatic ring derivative having hiv integrase inhibitory activity
GB0406282D0 (en) * 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Therapeutic compounds
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
EA201290808A1 (en) 2010-02-18 2013-03-29 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи SUBSTITUTED CONDENSED DERIVATIVES OF IMIDAZOL, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR USE
DE102011111991A1 (en) 2011-08-30 2013-02-28 Lead Discovery Center Gmbh New cyclosporin derivatives
ME02424B (en) * 2011-11-29 2016-09-20 Perosphere Inc ANTI-DESTROYING REVERSE
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
US12410191B2 (en) * 2019-05-21 2025-09-09 Zhejiang Hisun Pharmaceutical Co., Ltd. Macrolide derivatives, preparation method and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3105837A (en) * 1961-10-20 1963-10-01 Upjohn Co 2, 2'-alkylenebisbenzimidazoles
US3210370A (en) * 1964-06-22 1965-10-05 Upjohn Co Process for preparing 2, 2'-methylene-bisareneimiazoles
IL111011A0 (en) * 1993-09-22 1994-11-28 Wellcome Found Bisbenzimidazole compounds, their preparation and pharmaceutical compositions containing them
US6815461B1 (en) * 1994-01-20 2004-11-09 The University Of North Carolina At Chapel Hill Method of inhibiting retroviral integrase
US5693515A (en) * 1995-04-28 1997-12-02 Arris Pharmaceutical Corporation Metal complexed serine protease inhibitors

Also Published As

Publication number Publication date
EE9900477A (en) 2000-06-15
NO314183B1 (en) 2003-02-10
AU752064B2 (en) 2002-09-05
NO994858D0 (en) 1999-10-06
SI20115A (en) 2000-06-30
CA2285454A1 (en) 1998-10-15
CN1251579A (en) 2000-04-26
PL336233A1 (en) 2000-06-19
LV12495A (en) 2000-06-20
KR20010006119A (en) 2001-01-26
LV12495B (en) 2001-01-20
AU5895098A (en) 1998-10-30
NO994858L (en) 1999-12-06
JP2001519806A (en) 2001-10-23
SK136799A3 (en) 2000-07-11
EP1019382A1 (en) 2000-07-19
WO1998045275A1 (en) 1998-10-15
LT4704B (en) 2000-09-25
HUP0001522A2 (en) 2001-05-28
EE04055B1 (en) 2003-06-16
NZ500029A (en) 2001-02-23
HUP0001522A3 (en) 2001-08-28

Similar Documents

Publication Publication Date Title
LT99131A (en) Compounds and compositions for treating diseases associated with serine protease, particularly tryptase, acitivity
DE69727586D1 (en) Cysteine protease inhibitoren
ZA992447B (en) Quinoxalinones as serine protease inhibitors.
ZA957263B (en) Improved proteolytic enzyme cleaner.
HUP0203506A3 (en) Modified peptides as therapeutic agents
ZA983629B (en) Serine protease inhibitors
ZA992448B (en) Quinoxalinones as serine protease inhibitors.
AU3967097A (en) Novel compounds and compositions for treating diseases associated with tryptase activity
AU7127298A (en) Serine protease inhibitors
HUP9901187A3 (en) Serine protease inhibitors
ZA992445B (en) Benzoxazinones/benzothiazinones as serine protease inhibitors.
ZA971733B (en) Serine protease inhibitors.
AU7471598A (en) Human serine protease precursor
ZA971667B (en) Serine protease inhibitors.
EP1179052A4 (en) Serine proteases
ZA99733B (en) Ophthalmic composition.
EP0674001A3 (en) Novel protease for treating devitalized tissue.
GB9800817D0 (en) Serine protease inhibitors
AU5290499A (en) Human htra serine protease
ZA200003377B (en) Serine carbonates.
AU3519299A (en) Human casb12 polypeptide, a serine protease
EP1132473A4 (en) Novel serine protease bssp6
EP1001965A4 (en) Tissue plasminogen activator-like protease
AU1624501A (en) Human serine protease
AU1730797A (en) 3-substituted-4-oxa-1-azabicyclo{3,2,0}heptan-7-one as cysteine protease inhibitors

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20031201